Close 2026-08-21 1267 scanned A

MARKSANS

Marksans Pharma Limited
HealthcareMid capRs 14,560 crRs 40.0 cr traded a day
Close on 2026-08-21
321.30
+0.14%
52-week range93% of the way up
156.89333.00
Market cap
14,560 cr
P/E (TTM)
27.9×
industry 44×
EPS (TTM)
11.50
Revenue YoY
+35.6%
Q1 FY27
Profit YoY
+173.9%
Net margin
19.0%
+9.6pt vs a year ago
Growth trend
-1072.8pt
vs last quarter’s YoY
1 month
+30.6%
Below 52w high
3.6%
RSI (14)
77
overbought
Daily swing
4.7%
average true range
Volume
0.5×
vs 20-day average
Traded
Rs 40 cr
median day
Close200-day averageMaterial filing
200300Aug 25Oct 25Dec 25Feb 26Apr 26Jun 26Aug 26
260 sessions · hover for the filing behind a move
1 week
−3.51%
1 month
+30.56%
3 months
+26.10%
6 months
+81.72%
1 year
+87.95%

The read

written from the numbers on this page
The evidence leans constructive9 supporting, 0 against, 1 worth knowing

Supporting

  • trading 54% above its 200-day average
  • sitting at 93% of its 52-week range, with little overhead supply from trapped buyers
  • up 88% over twelve months
  • matches stretched far above trend, which has beaten the market by +0.82 points over 20 sessions across 27,715 past signals
  • 2 of the scans it matches have a positive measured record
  • 5 independent kinds of evidence agree today, which is uncommon
  • revenue grew 36% year on year in the quarter ending 2026-06-30
  • net margin has widened from 13.8% to 19.0% across four quarters
  • priced at 28× earnings against an industry median of 44× — 37% below its peers

Against

  • nothing the data supports either way

Worth knowing

  • RSI at 77 is stretched; strong stocks stay stretched for a long time, so this is a note on entry timing, not on direction
What would change this read: a close below 208, its 200-day average; a failure to hold the top of its 52-week range.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.

What is working, what is not

read from the filings, with the figure behind every line
Working3

Net profit +173.9% year on year, Rs 58 cr to Rs 159 cr.

+173.9%Rs 58 crRs 159 cr

Profit grew faster than revenue, +173.9% against +35.6%.

+173.9%+35.6%

Net margin moved from 9.4% to 19.0%.

9.4%19.0%
Needs watching
Nothing in the filings stands out either way.
Every figure here is computed from the company’s own filings. The wording is generated directly from the figures.

How it has performed

price return over each window, measured against zero
-3.5%1W+30.6%1M+26.1%3M+81.7%6M+87.9%1Y

What the scans say today

15 of 47 matched on 2026-08-21
MARKSANS matches 15 of the 47 scans today, across 5 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.

Quality of the business

balance sheet as at 2026-03-31
Return on equity
17.2%
trailing profit over shareholders’ funds
Return on capital
22.6%
pre-tax profit over equity plus borrowings
Debt to equity
0.01×
30 cr borrowed against 3,023 cr of equity
Net debt
605 cr
cash exceeds borrowings
Cash conversion
88%
operating cash flow as a share of profit
Receivable days
74
how long customers take to pay
Return on capital uses profit before tax over equity plus borrowings. The textbook version adds finance costs back; those are not tagged reliably in quarterly filings, so this understates the ratio for a heavily borrowed company rather than flattering it. Balance sheets are filed half-yearly, so these can be up to six months behind the profit figures above.

Valuation against its own history

500 sessions since 2024-09-06
26×
median 30×
41×
now 28×
MARKSANS trades at 28× trailing earnings, close to its median of 30× over this window. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.

Recent filings

from the exchange, newest first
Results filings were typically -0.52pt vs the market over the next 5 sessions (n=7,520) · Analyst call filings were typically +0.14pt vs the market over the next 5 sessions (n=3,352)

The business

from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
6426827162072075485684115.2%9.4%19.0%Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.

Going for it

  • revenue grew 36% against the same quarter a year earlier
  • profit rose 174% year on year
  • net margin widened from 17.4% to 19.0%
  • revenue rose in 3 of the last 4 quarters

Going against it

  • nothing clear in the filed numbers
Quarter-by-quarter numbers, as filed
QuarterRevenueProfit before taxNet profitEPSNet margin
Q1 FY27
2026-06-30 · consolidated
8412071593.4719.0%
Q4 FY26
2026-03-31 · consolidated
8562001493.2717.4%
Q3 FY26
2025-12-31 · consolidated
7541511142.5015.1%
Q2 FY26
2025-09-30 · consolidated
720133992.1713.8%
Q1 FY26
2025-06-30 · consolidated
62077581.299.4%
Q4 FY25
2025-03-31 · consolidated
711292.0012.8%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.

Where the price stands

the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+17.9%
Versus 200-day average+54.2%
Below 52-week high-3.5%
Above 52-week low+104.8%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)76.6
Higher closes in last 52 of 5
Six-month return+81.72%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)4.71%
Volume versus 20-day0.5x
Median daily turnoverRs 40.0 cr

Peers

Healthcare · 67 classified companies
MARKSANS trades at 27.9× trailing earnings against an industry median of 44.0× across 64 other classified companies in its industry — cheaper than them, by 37%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.
CompanyMarket cap (Rs cr)P/E1 month1 yearTurnover (Rs cr)
SUNPHARMA456,44338.3−2.64%+21.54%363.8
DIVISLAB227,82077.9+17.69%+40.46%315.4
TORNTPHARM165,72780.1−3.33%+36.66%212.0
APOLLOHOSP125,00557.6−1.91%+13.16%257.5
CIPLA115,70034.5+2.81%−8.73%119.7
ZYDUSLIFE111,77625.5+0.56%+12.44%112.7
LUPIN100,67718.1−8.12%+16.52%259.0
MANKIND98,45947.6−6.78%−6.26%81.8
DRREDDY98,08730.8+0.72%−6.30%205.2
LAURUSLABS97,35389.3+14.90%+109.51%286.4
MAXHEALTH97,32466.8−7.77%−13.93%185.4
MARKSANS14,56027.9+30.56%+87.95%40.0
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet

Recent sessions

what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.
SessionScansWhich
2026-08-181Short averages stacked in order